Clinical studies with ropinirole in Parkinson’s disease and RLS
- Cite this article as:
- Jost, W.H., Angersbach, D. & Rascol, O. J Neurol (2006) 253(Suppl 4): iv16. doi:10.1007/s00415-006-4004-4
- 71 Downloads
Ropinirole is a modern dopamine agonist with a halflife of medium extent that is highly selective for D2-receptors. Ropinirole is an indole derivative and thus does not belong to the group of ergoline dopamine receptor agonists. Its effect has been proved in a number of controlled studies in both monotherapy and combination treatments of Parkinson’s disease. We can meanwhile refer to the long-term data of studies that have been run for more than 10 years. The substance has also been approved for the management of restless legs syndrome. A long-acting formula of the substance will be available soon.